Jubilant Ingrevia's Q4 profits increased by 17%, reaching ₹86.4 crore, with revenues also up by 12% at ₹1,178.7 crore. The EBITDA grew by 10.5%, but the profit margin slightly decreased to 13.8%.

Jubilant Ingrevia reported a 10.9% increase in Q4 EBITDA, reaching INR 1.63 billion compared to the previous year, with a slight decrease in margin to 13.8%.

Anticipation builds for Jubilant Ingrevia's Q4 financial results, which are set to be released soon. Investors will closely watch these numbers for insights into the company's performance during the quarter.

Jubilant Ingrevia announces a proposed final dividend of INR 2.5 per share for the fiscal year 2026, subject to approval at the upcoming AGM. Additionally, they have reappointed J.K. Kabra & Co. as cost auditors for fiscal year 2027 and set July 24, 2026, as the record date.

Jubilant Ingrevia aims to triple revenue and quadruple EBITDA through a focus on specialty chemicals under the Pinnacle345 strategy, also boasting a robust pipeline, unique products, and expansion of capacities. The company aims to achieve a 20% EBITDA margin and 15% ROCE by fiscal years 29-30.

Jubilant Ingrevia has confirmed that there's no undisclosed information that could impact its share price. The company emphasizes commitment to promptly sharing all price-relevant details with the stock exchanges.

Axis Securities recommends buying Jubilant Ingrevia shares, expecting them to reach ₹800 due to its focus on high-margin Specialty Chemicals and CDMO services. The company's strategic investments and new contracts indicate potential for significant growth, with projected revenue, EBITDA, and PAT CAGR of 13%, 20%, and 22% respectively by FY28.

Kotak Securities suggests investing in Jubilant Ingrevia and Vishal Mega Mart due to their promising growth prospects. Vishal Mega Mart is poised for expansion, while Jubilant Ingrevia focuses on high-margin specialty chemicals to fuel future growth.

Jubilant Ingrevia has officially taken over Remidex Pharma, securing a full ownership position as per the deal announced on March 13, 2026. This acquisition is expected to strengthen Jubilant Ingrevia's pharmaceutical portfolio significantly.